London
A breast cancer patient this week sued Britain’s National Health Service for refusing to give her a drug that could save her life. Elaine Barber, a 41-year-old mother of four, was told that prescribing Herceptin, a new drug that costs up to $50,000 a year per patient, was not “a cost-effective use of finite health resources.” Last month, though, a different patient was given the drug on the grounds that her status as a single mother of a disabled child rendered her case “exceptional.” In most E.U. countries, drugs are made available through public health systems as soon as they get an E.U. license. But in Britain, drugs must also undergo a cost-benefit analysis.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
-
5 high rating cartoons about Biden's low poll numbersCartoons Artists take on checklists, ice creams, and more
-
A gastronomic tour of the Costa de la LuzThe Week Recommends This Spanish spot has fantastic restaurants "rooted in the region's distinctive produce"
-
Crossword: May 19, 2024The Week's daily crossword
